PBYI Puma Biotechnology
- 4.860
- -0.100-2.02%
- 4.920
- +0.060+1.23%
Puma Biotechnology News
HC Wainwright & Co. : The Puma Biotechnology (PBYI.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $7.00.
Puma Biotechnology Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Puma Biotechnology, Maintains $7 Price Target
Puma Biotechnology (PBYI) Receives a Sell From Barclays
Buy Rating Affirmed for Puma Biotechnology Amid Strong Q1 Performance and Promising Outlook
Puma Biotechnology Analyst Ratings
Buy Rating on Puma Biotechnology Amid Financial Challenges and Drug Advancement Prospects
Analysts' Opinions Are Mixed on These Healthcare Stocks: Jazz Pharmaceuticals (JAZZ), Puma Biotechnology (PBYI) and MoonLake Immunotherapeutics (MLTX)
Puma Biotechnology: Hold Rating Justified by Underwhelming Sales and Limited Growth Outlook
HC Wainwright & Co. Reiterates Buy on Puma Biotechnology, Maintains $8 Price Target
Puma Biotechnology Analyst Ratings
Analysts Are Bullish on Top Healthcare Stocks: Puma Biotechnology (PBYI), ESSA Pharma (EPIX)
Edward White's Buy Rating for Puma Biotechnology: Strong Financial Performance and Promising Market Potential for Nerlynx
Hold Rating on Puma Biotechnology: A Comprehensive Analysis of Q3 Performance and Future Prospects
Buy Rating for Puma Biotechnology: Key Factors and Financial Prospects
HC Wainwright & Co. Reiterates Buy on Puma Biotechnology, Maintains $8 Price Target
Puma Biotechnology Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Rani Therapeutics Holdings (RANI), Puma Biotechnology (PBYI) and BeiGene (BGNE)
Puma Biotechnology Analyst Ratings
Puma Biotechnology (PBYI) Gets a Sell From Barclays
Analysis
Price Target
No Data
